Cargando…

Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study

Detalles Bibliográficos
Autores principales:	Yan, Yan, Davgadorj, Chantsalmaa, Lyu, Chunyan, Zhang, Shiliang, Qiu, Yuanwang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254457/ https://www.ncbi.nlm.nih.gov/pubmed/35803384 http://dx.doi.org/10.1016/j.jinf.2022.06.032

Ejemplares similares

Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection
por: Yan, Yan, et al.
Publicado: (2022)

Corrigendum: Novel molecular therapeutics targeting signaling pathway to control hepatitis B viral infection
por: Yan, Yan, et al.
Publicado: (2023)

CCL19 enhances CD8(+) T-cell responses and accelerates HBV clearance
por: Yan, Yan, et al.
Publicado: (2021)

Characterizing COVID-19 severity, epidemiology and SARS-CoV-2 genotypes in a regional business hub of China
por: Yan, Yan, et al.
Publicado: (2021)

Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents
por: Leung, Daniel, et al.
Publicado: (2023)

Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine
por: Leung, Nancy H L, et al.
Publicado: (2022)

A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2023)

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
por: Vergori, Alessandra, et al.
Publicado: (2022)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
por: Yorsaeng, Ritthideach, et al.
Publicado: (2022)

Third dose of anti-SARS-CoV-2 inactivated vaccine for patients with RA: Focusing on immunogenicity and effects of RA drugs
por: Zhao, Ting, et al.
Publicado: (2022)

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients
por: Yang, Lei, et al.
Publicado: (2023)

Immunogenicity of Fractional Dose Inactivated Poliovirus Vaccine in India
por: Ahmad, Mohammad, et al.
Publicado: (2021)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
por: Zhan, Haoting, et al.
Publicado: (2023)

Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus
por: Ayers, Victoria B., et al.
Publicado: (2023)

Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2022)

Inactivated COVID-19 vaccines, HBV and HIV: Correspondence
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China
por: Han, Xiaoxu, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China
por: Yi, Yunyun, et al.
Publicado: (2023)

The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy
por: Coppola, Nicola, et al.
Publicado: (2015)

Immunogenicity of inactivated rotavirus in rhesus monkey, and assessment of immunologic mechanisms
por: Zhou, Yan, et al.
Publicado: (2023)

An inactivated vaccine made from a U.S. field isolate of porcine epidemic disease virus is immunogenic in pigs as demonstrated by a dose-titration
por: Collin, Emily A, et al.
Publicado: (2015)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
por: Tangsathapornpong, Auchara, et al.
Publicado: (2023)

Immunogenicity of SARS inactivated vaccine in BALB/c mice
por: Xiong, Sheng, et al.
Publicado: (2004)

Immunogenicity of an Inactivated Canine Adenovirus Type 1 Vaccine for Foxes
por: Fu, Yang, et al.
Publicado: (2022)

Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine
por: Chen, Qian, et al.
Publicado: (2023)

High-rise buildings: A risk factor in the COVID-19 Omicron epidemic period
por: Lyu, Hongxin, et al.
Publicado: (2023)

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV
por: Cargill, Tamsin, et al.
Publicado: (2023)

Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants
por: Seki, Yohei, et al.
Publicado: (2022)

The third coronavirus epidemic in the third millennium: what’s next?
por: Čivljak, Rok, et al.
Publicado: (2020)

Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants
por: Lalwani, Sanjay K., et al.
Publicado: (2016)

The impact of the Omicron epidemic on the health behavior in Cape Town, South Africa
por: Lin, Xiao-Qing, et al.
Publicado: (2022)

1059 Expanded immunogenicity of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine in older adults
por: Diazgranados, Carlos, et al.
Publicado: (2014)

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer
por: Fendler, Annika, et al.
Publicado: (2022)

Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
por: Ong, Chon Phin, et al.
Publicado: (2023)

Experimental studies on the inactivation of HBV in blood via riboflavin photochemical treatment
por: Zhou, Zi-Yu, et al.
Publicado: (2017)

Modeling and Analyzing the Transmission Dynamics of HBV Epidemic in Xinjiang, China
por: Zhang, Tailei, et al.
Publicado: (2015)

A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial
por: Cao, Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5qo9es4k1tkar6737rdu3t49un